NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had disease progression while on Herceptin/trastuzumab for the treatment of HER2+ MBC
Exclusions: Patients who have received more than 3 lines of therapy in the setting of metastatic disease; Patients previously treated with any form of adoptive cell transfer therapy; Patients with uncontrolled brain metastases or leptomeningeal disease

Comments are closed.

Up ↑